We are live on ! Find out more
PFM

Privium Fund Management Portfolio holdings

AUM $544M
1-Year Est. Return 72.49%
This Fund
S&P 500
This Quarter Est. Return
+47.05%
1 Year Est. Return
+72.49%
3 Year Est. Return
+451.42%
5 Year Est. Return
10 Year Est. Return
AUM
$442M
AUM Growth
+$39.9M
Cap. Flow
-$47.3M
Cap. Flow %
-10.69%
Top 10 Hldgs %
74.18%
Holding
92
New
10
Increased
24
Reduced
15
Closed
28

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 32.85%
2 Healthcare 24.76%
3 Technology 23.63%
4 Communication Services 14.68%
5 Industrials 1.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TSLA icon
1
Tesla
TSLA
$1.38T
$88.8M 20.1%
220,000
+4,000
+2% +$1.29M
SPOT icon
2
Spotify
SPOT
$113B
$64.9M 14.68%
145,000
-4,000
-3% -$1.71M
SHOP icon
3
Shopify
SHOP
$197B
$44.1M 9.99%
415,000
AMZN icon
4
Amazon
AMZN
$2.87T
$30.9M 7%
141,000
PLTR icon
5
Palantir
PLTR
$448B
$28M 6.33%
370,000
-105,000
-22% -$6.12M
SE icon
6
Sea Limited
SE
$73.1B
$22.3M 5.04%
210,000
PRQR icon
7
ProQR Therapeutics
PRQR
$323M
$13.2M 2.99%
4,985,633
-646,755
-11% -$2.05M
QURE icon
8
uniQure
QURE
$3.38B
$13.1M 2.97%
742,162
-2,754
-0.4% -$23.8K
SNOW icon
9
Snowflake
SNOW
$114B
$11.6M 2.62%
75,000
-20,000
-21% -$2.82M
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.52B
$10.9M 2.46%
258,380
+15,868
+7% +$787K
NVDA icon
11
NVIDIA
NVDA
$5.25T
$9.8M 2.22%
73,000
IONS icon
12
Ionis Pharmaceuticals
IONS
$10.1B
$9.33M 2.11%
266,794
+16,050
+6% +$600K
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.11M 1.84%
97,154
-20,829
-18% -$1.71M
MRK icon
14
Merck
MRK
$366B
$7.22M 1.63%
72,611
+12,500
+21% +$1.29M
ARWR icon
15
Arrowhead Research
ARWR
$12B
$7.16M 1.62%
380,586
+47,230
+14% +$973K
NET icon
16
Cloudflare
NET
$107B
$6.46M 1.46%
60,000
SMR icon
17
NuScale Power
SMR
$3.81B
$6.45M 1.46%
+360,001
New +$7.43M
AXSM icon
18
Axsome Therapeutics
AXSM
$10.4B
$5.27M 1.19%
62,232
-18,000
-22% -$1.66M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$424M
$5M 1.13%
397,650
+102,850
+35% +$1.55M
ZLAB icon
20
Zai Lab
ZLAB
$2.93B
$4.85M 1.1%
185,062
-30,562
-14% -$848K
ARQT icon
21
Arcutis Biotherapeutics
ARQT
$2.99B
$4.54M 1.03%
+325,709
New +$3.57M
IONQ.WS
22
IonQ Inc Warrants
IONQ.WS
$6.69B
$3.9M 0.88%
+128,001
New +$1.9M
MRNA icon
23
Moderna
MRNA
$55.1B
$3.43M 0.78%
82,476
+41,994
+104% +$2.01M
CPNG icon
24
Coupang
CPNG
$29.7B
$3.12M 0.71%
141,900
-60,000
-30% -$1.47M
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$5.02B
$2.72M 0.62%
148,400

Similar funds

Privium Fund Management's Q4 2024 Portfolio in Review

As of Q4 2024, Privium Fund Management held 92 positions worth $442M, up 9.9% from $402M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Privium Fund Management withdrew a net $47.3M in Q4 2024, closing 28 positions and reducing 15 holdings. Its most notable exit was Datadog, an estimated $7.57M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 33% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Privium Fund Management opened a new position in NuScale Power worth $6.45M.

  • Privium Fund Management's largest Q4 2024 buy was NuScale Power: 360,001 shares worth $6.45M.
  • Privium Fund Management added most to Moderna in Q4 2024, an estimated $2.01M increase.
  • Privium Fund Management's biggest Q4 2024 reduction was AST SpaceMobile, cutting an estimated $17.3M.
  • Privium Fund Management fully exited Datadog in Q4 2024, selling an estimated $7.57M.
  • Privium Fund Management's ten largest holdings make up 74% of its $442M portfolio in Q4 2024.
  • Privium Fund Management opened 10 new positions and closed 28 in Q4 2024.
  • Privium Fund Management's portfolio value rose 9.9% quarter-over-quarter to $442M.

Based on Privium Fund Management's 13F filing for Q4 2024, filed 11 Feb 2025.